Leading BioSolutions Platform

Financial Results: Q2 FY2020 Crore FY 20 FY 19 Particulars Q-2 Reported PPA / Integration Q-2* (Note 1) Q-2* % Change % % (Note 2) Total Revenue from operation 7,817 7,817 100% 4,257 100% 84% Variable Cost 4,548 2 4,546 58% 2,406 57% || Gross Margin 3,269 (2) 3,271 42% 1,851 43% 77% Fixed Overheads EBITDA 1,730 1,730 22% 1,012 24% 1,539 (2) 1,541 20% 839 20% 84% Other Income / (Loss) (68) (68) (20) Amortization / Depreciation 609 152 457 181 Finance Cost 381 381 181 PBT 481 (154) 635 8% 457 11% 39% Tax 66 (46) 112 116 PAT 415 (108) 523 7% 341 8% 53% Income/(Loss) from Associate Co. and JV (8) (8) (8) Minority Interest 13 13 6 Profit After Tax, Associate Income & 395 (108) 502 6% 327 8% 54% Minority Interest Exceptional Cost 305 305 57 Net Profit 90 (108) 197 3% 270 6% -27% Note: UPL 1) Purchase Price Allocation effect and Integration cost are removed from Q2 FY2020. However in variable cost the amount of Rs. 2 crore is due to foreign currency translation impact. 2) Previous years numbers (without Arysta) have been regrouped for comparison purpose. 3) Exceptional cost includes full provision of Rs. 217 crore towards Jury verdict on Agrofresh litigation, Rs. 88 crore are towards redundancy and other integration related costs 47

View entire presentation